NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 21 hours 59 min ago

Closing February and March 2018 Application Receipt Dates for PAR-13-129 Occupational Safety and Health Research (R01)

Thu, 11/02/2017 - 13:02
Notice NOT-OH-18-006 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Correction to Key Dates for RFA-CA-17-044 "Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)"

Thu, 11/02/2017 - 12:59
Notice NOT-CA-18-019 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Request for Information (RFI): Inviting comments and suggestions on the development of a Eureka prize for Alzheimer's disease research

Thu, 11/02/2017 - 12:46
Notice NOT-AG-17-018 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Request for Information (RFI): Information Resources on Lifestyle and Behavioral Factors Contributing to the Effectiveness of Cancer Therapies

Thu, 11/02/2017 - 12:35
Notice NOT-CA-18-002 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)

Thu, 11/02/2017 - 11:45
Funding Opportunity PAR-18-118 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated clinical trials of mind and body interventions in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a clinical trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention are critical for changes in outcome; assessing whether the intervention can be delivered with fidelity across sites in preparation for a future multi-site trial; or collect additional preliminary data such as determining the duration or frequency of the intervention to be used in a future multi-site trial. It is important, therefore, to already have sufficient preliminary data that includes: demonstration of feasibility of recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; and evidence that the intervention has promise of clinical benefit. This FOA is not intended to support multi-site efficacy or effectiveness trials, nor will it support trials to test mind and body interventions for the treatment or prevention of cancer.
Categories: NIH-Funding

Improving Outcomes for Disorders of Human Communication (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 11:18
Funding Opportunity PA-18-288 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the health outcomes for individuals with deafness and other communication disorders through effectiveness and health services research in the NIDCD mission areas of hearing, balance, smell, taste, voice, speech and language.
Categories: NIH-Funding

Improving Outcomes for Disorders of Human Communication (R01 Clinical Trial Optional)

Thu, 11/02/2017 - 11:15
Funding Opportunity PA-18-287 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the health outcomes for individuals with deafness and other communication disorders through effectiveness and health services research in the NIDCD mission areas of hearing, balance, smell, taste, voice, speech and language.
Categories: NIH-Funding

Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33 Clinical Trial Required)

Thu, 11/02/2017 - 11:02
Funding Opportunity PAR-18-115 from the NIH Guide for Grants and Contracts. Understanding the mechanisms by which complementary or integrative Mind and Body Interventions exert their clinical effects is critical for the development of optimized interventions that target specific conditions and disorders.
Categories: NIH-Funding

Phased Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R61/R33 Clinical Trial Required)

Thu, 11/02/2017 - 10:58
Funding Opportunity PAR-18-114 from the NIH Guide for Grants and Contracts. Understanding the mechanisms by which complementary or integrative Mind and Body Interventions exert their clinical effects is critical for the development of optimized interventions that target specific conditions and disorders.
Categories: NIH-Funding

Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 10:52
Funding Opportunity PAR-18-112 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.
Categories: NIH-Funding

Studies at Periviable Gestation (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 10:46
Funding Opportunity PA-18-097 from the NIH Guide for Grants and Contracts. The goals of this Funding Opportunity Announcement (FOA) are to focus on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.
Categories: NIH-Funding

Advancing Understanding, Prevention and Management of Infections Transmitted from Women to their Infants (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 10:40
Funding Opportunity PA-18-092 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.
Categories: NIH-Funding

Prescription Drug Abuse (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 10:37
Funding Opportunity PA-18-076 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
Categories: NIH-Funding

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional)

Thu, 11/02/2017 - 10:32
Funding Opportunity PA-18-075 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R21) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs).
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional)

Thu, 11/02/2017 - 10:29
Funding Opportunity PA-18-074 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage investigators to propose discrete well-defined projects that can be completed within two years. Projects of interest fall within the research domain of behavioral or integrated (e.g., behavioral and pharmacological) interventions targeting: (a) substance abuse; (b) prevention of acquisition or transmission of HIV infection among individuals in drug abuse treatment; (c) promotion of adherence to drug abuse treatment, HIV and addiction medications; and (d) chronic pain. Specific examples include, but are not limited to studies focusing on: 1) Stage I intervention generation; 2) Stage I pilot or feasibility and both should include the development of putative moderators, mediators, and change mechanisms; (3) Stage I studies to generate or refine drug abuse treatment or adherence interventions; (4) Stage I research to boost effects and increase implementability of interventions with creative use of technology or through other means.
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

Thu, 11/02/2017 - 10:26
Funding Opportunity PA-18-073 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage investigators to propose discrete well-defined projects that can be completed within three years. Projects of interest fall within the research domain of behavioral or integrated (e.g., behavioral and pharmacological) interventions targeting: (a) substance abuse; (b) prevention of acquisition or transmission of HIV infection among individuals in substance abuse treatment; (c) promotion of adherence to substance abuse treatment, HIV and addiction medications; and (d) chronic pain. Specific examples include, but are not limited to studies focusing on: 1) Stage I intervention generation; 2) Stage I pilot or feasibility and both should include the development of putative targets/ moderators, mediators, and change mechanisms;(3) Stage I studies to generate or refine substance abuse treatment or adherence interventions for use in primary care; (4) Stage I research to boost effects and increase implementability of interventions with creative use of technology or other means.
Categories: NIH-Funding

Prescription Drug Abuse (R01 Clinical Trial Optional)

Thu, 11/02/2017 - 10:23
Funding Opportunity PA-18-058 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
Categories: NIH-Funding

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional)

Thu, 11/02/2017 - 10:20
Funding Opportunity PA-18-056 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs).
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)

Thu, 11/02/2017 - 10:18
Funding Opportunity PA-18-055 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) drug abuse treatment and adherence interventions for use in primary care; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.
Categories: NIH-Funding

Studies at Periviable Gestation (R03 Clinical Trial Optional)

Thu, 11/02/2017 - 10:09
Funding Opportunity PA-18-053 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.
Categories: NIH-Funding